The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cause of death among patients with non-small cell lung cancer treated with postoperative radiation therapy (PORT).
 
Aashray Singareddy
No Relationships to Disclose
 
Saiama Naheed Waqar
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Siddhartha Devarakonda
No Relationships to Disclose
 
Jeffrey P. Ward
Employment - Millipore (I)
Consulting or Advisory Role - Guidepoint Inc; Novocure
Travel, Accommodations, Expenses - Halozyme
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech/Abbvie; Geneplus
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Ignyta; Janssen; Jounce Therapeutics; Lilly; Merck Serono; Nektar; Pfizer; Phillips Gilmore Oncology; Roche
 
Clifford Robinson
Leadership - Radialogica
Stock and Other Ownership Interests - Radialogica
Consulting or Advisory Role - AstraZeneca; EMD Serono; Varian Medical Systems
Research Funding - Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1; U.S. Provisional Application No. 62/598,162 Entitled SYSTEM AND METHOD FOR DETERMINING SEGMENTS FOR ABLATION
Travel, Accommodations, Expenses - Siemens Healthineers
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; G1 Therapeutics; Gilead Sciences; PharmaMar; Takeda
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst)
 
Pamela Parker Samson
No Relationships to Disclose